All News

GSK forms the Oncology Clinical and Translational Consortium, a scientific research network comprised of six international cancer centers.

OGD is under pressure to improve review operations.

Bristol-Myers Squibb has elected Thomas Lynch, Jr., MD to its board of directors.

Alvotech plans investment in biosimilars portfolio and manufacturing facility.

LSNE appoints Shawn Cain as COO, a new position within the company.

EMA revises its polices on fee reductions for orphan drugs for 2014.

TxCell has received manufacturing accreditation status of its cell-therapy production site in Besancon, France, from the French National Agency for Drug Safety (ANSM).

SGS Life Science Services announced that its bioanalytical laboratory in Poitiers, France has received GMP certification, following approval from ANSM.

Drug Quality and Security Act gives FDA authority over compounding pharmacies.

The international “Fight the Fakes” campaign will raise awareness about the dangers of counterfeit medicines.

The Indiana Biosciences Research Institute will accelerate collaboration and focus on human-health solutions.

Additional companies join Merck KGaA and Neviah Genomics in the Israel BioIncubator.

Almac releases an enhanced third-party logistics customer billing application.

GSK and Amicus Therapeutics revise Fabry agreement entered into in July 2012.

GlaxoSmithKline plans to invest nearly $41 million to expand its operations at its facility in Montrose, the United Kingdom.

Thermo Fisher must divest of cell culture media and sera lines, and other businesses, in purchase of Life Technologies.

Coldstream Laboratories names director of formulation development.

Pure MHC and Catalent sign an agreement to develop RL21A using Catalent's GPEx technology.

Catalent opens clinical-trial supply facility in Shanghai, China.

Mylan and the Indian biopharmaceutical company Biocon receive approval for a biosimilar version of trastuzumab in India. Also, Mylan and Teva reach settlement on Copaxone in the EU.

European Medicines Agency announces the launch of the Accelerated development of vaccine benefit-risk collaboration in Europe (ADVANCE) project.

Merck KGaA plans to build a new biomanufacturing facility in Nantong, China.

Catalent has signed a product development agreement with immunology company Pure MHC (major histocompatibility complex), which specializes in MHC-based diagnostics and therapeutics.

Phase I/II study to evaluate treatment of patients with melanoma using Pfizer’s palbociclib and GSK’s trametinib.

Annual growth in spending for medicines is expected to rise from 2-3% in 2013 to 5-7% in 2017, the highest pace of growth since 2009.

New CDMO to be formed from the combination of DSM Pharmaceutical Products and Patheon in a $2.6-billion transaction.

Covance Inc. and Pathoquest have announced a collaboration to provide next-generation sequencing based biosafety assessments to detect and identify viral contaminants within biologic compounds.

USP issues call for candidates for its 2015-2020 Council of Experts.

Ei Lilly announces investments in insulin manufacturing capacity for its sites in Indianapolis, Puerto Rico, France, and China.

Shire's agreement to acquire ViroPharma will strengthen its rare-disease portfolio.